Telomerase activity in acute myelogenous leukaemia: clinical and biological implications

We examined telomerase activity in myeloid leukaemic cell lines, normal haemopoietic cells, and leukaemic blasts from acute myelogenous leukaemia (AML) patients. Normal bone marrow mononuclear (BMNC) cells expressed low telomerase activity. Higher telomerase activity was detected in 10 myeloid leukaemic cell lines compared to normal BMNC cells. Treatment with 1,25(OH)2D3, and vitamin D3 analogues, EB1089 and KH1060, reduced telomerase activity in vitamin D3‐sensitive HL‐60 cells, whereas vitamin D3 insensitive K562 cells did not change its activity. This down‐regulation of telomerase activity by EB1089 was associated with induction of p21 protein. The rank order of telomerase activity was leukaemic CD34− cells > leukaemic CD34+ cells > normal CD34− cells > normal CD34+ cells. Telomerase activity was positive in all of the AML patients tested; however, heterogeneity of telomerase activity was found amongst this group. Therefore we compared telomerase activity with clinical response. Unexpectedly, we found that a higher rate of complete remission was noted in AML patients with higher telomerase activity. No association between telomerase activity and biological parameters including percentage of S‐phase, cytotoxicity to cytosine arabinoside and percentage of CD34+ cells in AML blasts was found. These results suggest that telomerase activity in AML patients is detected with high frequency, but is heterogenous. Expression level of telomerase activity may have a clinical implication in AML patients regarding clinical response.

[1]  H. Koeffler,et al.  Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts. , 1996, Leukemia.

[2]  M. Tsuchiya,et al.  Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. , 1996, Biochemical and biophysical research communications.

[3]  K. Riabowol,et al.  Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. , 1996, Cancer research.

[4]  J. Shay,et al.  Telomeres and telomerase in human leukemias. , 1996, Leukemia.

[5]  M. Mandal,et al.  Cell cycle-dependent modulation of telomerase activity in tumor cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Levine,et al.  Regulated expression of telomerase activity in human T lymphocyte development and activation , 1996, The Journal of experimental medicine.

[7]  J. Shay,et al.  Regulation of telomerase activity in immortal cell lines , 1996, Molecular and cellular biology.

[8]  E. Estey,et al.  Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  E. Dmitrovsky,et al.  Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. , 1996, Cancer research.

[10]  C. Harley,et al.  Differential Expression of Telomerase Activity in Hematopoietic Progenitors from Adult Human Bone Marrow , 1996, Stem cells.

[11]  M. Fackler,et al.  CD34: structure, biology, and clinical utility. , 1996, Blood.

[12]  A. Sartorelli,et al.  Differentiation of immortal cells inhibits telomerase activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Shay,et al.  Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. , 1995, Journal of immunology.

[14]  D. Broccoli,et al.  Telomerase activity in normal and malignant hematopoietic cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. S. Rhyu.  Telomeres, telomerase, and immortality. , 1995, Journal of the National Cancer Institute.

[16]  B. Leber,et al.  Telomerase activity in normal leukocytes and in hematologic malignancies. , 1995, Blood.

[17]  K. Kinzler,et al.  p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.

[18]  W. Mercer,et al.  p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. , 1995, Cancer research.

[19]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[20]  Z. Su,et al.  Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. , 1994, Oncogene.

[21]  C. Guillouf,et al.  Induction of p21 (WAF-1/CIP1) during differentiation. , 1994, Oncogene.

[22]  G. Roos,et al.  Telomerase activity in vivo in human malignant hematopoietic cells. , 1994, Oncogene.

[23]  C. Greider,et al.  Telomerase activity in germline and embryonic cells of Xenopus. , 1994, The EMBO journal.

[24]  S. de Vos,et al.  1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. , 1994, Leukemia research.

[25]  C. Harley,et al.  Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes , 1994, Journal of virology.

[26]  C. Harley,et al.  Telomerase activity in human ovarian carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. de Lange.  Activation of telomerase in a human tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Harley,et al.  Telomerase, cell immortality, and cancer. , 1994, Cold Spring Harbor symposia on quantitative biology.

[29]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[30]  C B Harley,et al.  Telomere length predicts replicative capacity of human fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C B Harley,et al.  Telomere end-replication problem and cell aging. , 1992, Journal of molecular biology.

[32]  J. Shay,et al.  Telomere positional effects and the regulation of cellular senescence. , 1992, Trends in genetics : TIG.

[33]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[34]  A. Wright,et al.  New insights into genetic eye disease. , 1992, Trends in genetics : TIG.

[35]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[36]  R. Myers,et al.  Structure and variability of human chromosome ends , 1990, Molecular and cellular biology.

[37]  T. Morgan,et al.  Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent. , 1990, Cytometry.

[38]  G. Morin.  The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats , 1989, Cell.

[39]  V A Zakian,et al.  Structure and function of telomeres. , 1989, Annual review of genetics.

[40]  S. Cole,et al.  Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. , 1988, Leukemia research.

[41]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[42]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[43]  H P Koeffler,et al.  Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. , 1983, Blood.

[44]  J. D. Watson.  Origin of Concatemeric T7DNA , 1972 .

[45]  J. Yudkin.  Sugar and Disease , 1972, Nature.

[46]  J. Watson.  Origin of concatemeric T7 DNA. , 1972, Nature: New biology.